详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

13| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China, [2]Department of Chinese Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China, [3]Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, China

出处：

DOI：

ISSN：

关键词： MAPK melanoma targeted therapy immunotherapy resistance

摘要：

In the past several decades, innovative research in cancer biology and immunology has contributed to novel therapeutics, such as targeted therapy and immunotherapy, which have transformed the management of patients with melanoma. Despite the remarkable therapeutic outcomes of targeted treatments targeting MAPK signaling and immunotherapy that suppresses immune checkpoints, some individuals acquire therapeutic resistance and disease recurrence. This review summarizes the current understanding of melanoma genetic variations and discusses individualized melanoma therapy options, particularly for advanced or metastatic melanoma, as well as potential drug resistance mechanisms. A deeper understanding of individualized treatment will assist in improving clinical outcomes for patients with cutaneous melanoma.Copyright © 2021 Zeng, Liu, Zhou and Zeng.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2019]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.5 最新[2023版] 4 最新五年平均 4.848 出版当年[2019版] 0 出版当年五年平均 4.137 出版前一年[2018版] 6.244 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China,

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1 alpha to re-activate MAPK signaling [2]Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. [3]Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer [4]Signaling pathways in rheumatoid arthritis: implications for targeted therapy [5]Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer [6]Local treatment of liver metastasis in a patient with advanced malignant melanoma: A case report [7]Editorial: Tumor microenvironment, immunotherapy, and drug resistance in breast and gastrointestinal cancer [8]Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance [9]MAPK信号转导通路与疼痛敏化调控研究进展 [10]Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance